Physician profile
Matthew Moeller
NPI 1386763704
$1,424.55
in general payments reported to CMS, 2019-2025
10 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2021: $12.01 · 2022: $51.65 · 2023: $14.08 · 2024: $399 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $43.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.59 |
| Education | $43.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $774.63 | 2022-2025 | Endoclot Phs, Single Use Repositionable Clip, Olympus |
| Erbe USA INC | $125.00 | 2019 | |
| Janssen Biotech, INC. | $93.87 | 2025 | Tremfya |
| Abbvie INC. | $92.98 | 2022-2025 | |
| Boston Scientific Corporation | $83.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.57 | 2021-2025 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $71.22 | 2022-2025 | Dupixent |
| Capsovision, INC. | $69.62 | 2024-2025 | Capsocam Plus |
| Daiichi Sankyo INC. | $18.43 | 2025 | Injectafer |
| Genzyme Corporation | $14.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Moeller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.